After breaking into the top 2% of UK businesses and passing the £100m annual turnover mark for the first time, buy-and-hold investor handl Group has announced the addition of two new brands to its growing health and wellbeing division.
Paediatric Specialist Physiotherapy (PSP) and Osiris Health will be joining handl Group to
strengthen the company’s neuro rehabilitation capabilities.
As both PSP and Osiris Health share the group’s ambitions, adding their industry-leading expertise to the group’s portfolio was an opportunity “too good to miss”.
Having already acquired Reach and launched Mind Right, handl Group had already made huge strides into the neuro rehabilitation market. When the opportunity arose to help PSP and Osiris Health scale up as part of the group’s portfolio and meet their growing demands for specialist rehabilitation, it was a simple decision to make.
handl chief strategy officer (CSO) Daniel Franklin (pictured) said: “handl Group’s success is built on growing the companies we invest in, and finding ways for them to build expanded service propositions.
“That’s exactly what PSP and Osiris Health needed, and it gives us the opportunity to link in
other brands such as Reach and Mind Right to offer a multi-disciplinary approach to neuro
rehabilitation.”
PSP’s Peter Sanderson remain with the business as clinical services director. He will be drawing on his specialisms in anatomy, chemo denervation and medicines optimisation and his experience as a national, European and international advisor on Spasticity management to help drive handl’s health and wellbeing division forwards. It’s an opportunity the honorary senior lecturer in neuro rehabilitation at UCLAN is keen to take.
He said: “I’d been exploring the opportunity to make PSP and Osiris Health a part of the handl Group for some time, and I’d built a great working relationship with Dan and the team.
“I’ll be able to continue the work we’ve started, keep the health and wellbeing division’s
vision aligned, and ensure that more patients than ever before have access to industry-leading clinical interventions and treatment.”
